Loading company…
Wilex AG develops antibody-drug conjugate cancer therapies using its proprietary ATAC technology, based in Munich, Germany.
Founded in 1997 in Munich, Germany, Wilex AG develops Antibody-Drug Conjugates (ADCs) that target cancer cells, using its proprietary ATAC technology, which uses Amanitin to overcome drug resistance. Jan Schmidt-Brand is CEO. The company has raised a total of EUR 27.10 mn, most recently a EUR 2.60 mn grant from the Federal Ministry of Education and Research in November 2006. In the latest fiscal year it reported revenue of EUR 10,643,788.60 and EBITDA of EUR -21,949,881.80.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in